Azithromycin ni antibayotiki jamii ya macrolide inayotumika kutibu maradhi mbalimali yanayosababishwa na bakteria wanaodhuriwa na dawa hii.
Kwanini azithromcine itumike kutibu maradhi yanayodhuriwa na vimelea tu?
Azithromycin inapaswa kutumika kutibu maradhiya vimelea wanaodhuriwa nayo ili kuzuia usugu wa vimelea hivyo kwenye dawa ambao umekuwa ukiongezeka.
Azithromycin hutibu magonjwa gani?
Azithromycin hutolewa na daktari katika matibabu yawagonjwa wenye dalili za kiasi hadi za wastani kama zilivyoelezewa hapa chini. Dozi na muda wa kutumia dozi huzingatiwa katika matibabu kwa kila mgonjwa.
Kumbuka
aUnapaswa kuwasiliana na daktari wako kwa ushauri zaidi na tiba.
Watu wazima
Azithromycin kwa watu wazima hutumika kutibu;
Maambukizi makali kwenye mapafu kutokana na bakteria Haemophilus influenzae, Moraxella catarrhalis auStreptococcus pneumoniae
Sinusaitizi kali kutokana na bakteria Haemophilus influenzae, Moraxella catarrhalis au Streptococcus pneumoniae
Nimonia ya jamii kutokana na bakteria Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae auStreptococcus pneumoniae
Pharyngitis/tonsillitis iliyosabaishwa na bakteria Streptococcus. Hufahamika pia kama ugonjwa wa tonses
Maambukizi ya wastani kwenye ngozi kutokana na bakteria Staphylococcus aureus, Streptococcus pyogenes, au Streptococcus agalactiae ( kwa mwenye usaha inapaswa afanyiwe upasuaji w akutoa usaha kwenye jipu)
Maambukizi kwenye urethra na shingo ya kizazi na via vingine za uzazi yanayosababishwa na bakteria Chlamydia trachomatis au Neisseria gonorrhoeae.
Vidonda sehemu za siri(chancroid) kutokana na bakteria Haemophilus ducreyi
Watoto
Azithromycin kwa watoto hutumika kutibu;
Maambukizi makali kwenye sikio kutokana na bakteria Haemophilus influenzae, Moraxella catarrhalis au Streptococcus pneumoniae
Nimonia ya jamii kutokana na bakteria Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae au Streptococcus pneumoniae
Pharyngitis/tonsillitis (tonses) inayosababishwa na bakteria Streptococcus pyogenes
Rejea za mada hii
Noedl H, et al. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis. 2006 Nov 15;43(10):1264-71. Epub 2006 Oct 12.
Peters DH, et al. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1992 Nov;44(5):750-99. doi: 10.2165/00003495-199244050-00007.
McMullan BJ, et al. Prescribing azithromycin. Aust Prescr. 2015 Jun;38(3):87-9. Epub 2015 Jun 1.
Fohner AE, et al. Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2017 Apr;27(4):164-167. doi: 10.1097/FPC.0000000000000270.
Champney WS, et al. Inhibition of 50S ribosomal subunit assembly in Haemophilus influenzae cells by azithromycin and erythromycin. Curr Microbiol. 2002 Jun;44(6):418-24.
Champney WS, et al. Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus. Antimicrob Agents Chemother. 1995 Sep;39(9):2141-4.
Dinos GP: The macrolide antibiotic renaissance. Br J Pharmacol. 2017 Sep;174(18):2967-2983. doi: 10.1111/bph.13936. Epub 2017 Aug 10.